Ocuphire Pharma, Inc.

NasdaqCM:OCUP Stock Report

Market Cap: US$43.6m

Ocuphire Pharma Management

Management criteria checks 1/4

Ocuphire Pharma's CEO is George Magrath, appointed in Nov 2023, has a tenure of less than a year. total yearly compensation is $3.15M, comprised of 3% salary and 97% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $50.40K. The average tenure of the management team and the board of directors is 0.6 years and 3.6 years respectively.

Key information

George Magrath

Chief executive officer

US$3.1m

Total compensation

CEO salary percentage3.0%
CEO tenureless than a year
CEO ownership0.1%
Management average tenureless than a year
Board average tenure3.6yrs

Recent management updates

Recent updates

Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

May 02
Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch

Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Mar 15
Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely

Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically

May 20
Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically

Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%

Apr 02
Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%

We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

Jan 27
We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

We Think Ocuphire Pharma (NASDAQ:OCUP) Needs To Drive Business Growth Carefully

Oct 08
We Think Ocuphire Pharma (NASDAQ:OCUP) Needs To Drive Business Growth Carefully

Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment

Sep 08

Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08

Aug 12

Ocuphire extends IP rights for lead candidate with new U.S. patent

Aug 03

Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics

Jun 29

We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

Jun 24
We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate

Is Ocuphire Pharma (NASDAQ:OCUP) In A Good Position To Invest In Growth?

Mar 22
Is Ocuphire Pharma (NASDAQ:OCUP) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation

Oct 08
Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation

Ocuphire Pharma: An Undervalued Ophthalmic Play

Aug 05

Ocuphire Pharma inks licensing deal for RX-3117 with Processa Pharma

Jun 17

Ocuphire Pharma (NASDAQ:OCUP) Is In A Good Position To Deliver On Growth Plans

Jun 11
Ocuphire Pharma (NASDAQ:OCUP) Is In A Good Position To Deliver On Growth Plans

Ocuphire drops 11% on $15M at-the money direct offering

Jun 04

Ocuphire Pharma EPS beats by $0.36

May 07

Do Institutions Own Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares?

Feb 08
Do Institutions Own Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares?

Ocuphire concludes enrollment in late-stage trial of Nyxol for dilated pupil condition

Jan 06

Ocuphire Pharma launches late-stage study of Nyxol in night vision disturbances

Jan 05

CEO Compensation Analysis

How has George Magrath's remuneration changed compared to Ocuphire Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$11m

Dec 31 2023US$3mUS$96k

-US$10m

Compensation vs Market: George's total compensation ($USD3.15M) is above average for companies of similar size in the US market ($USD667.11K).

Compensation vs Earnings: Insufficient data to compare George's compensation with company performance.


CEO

George Magrath (40 yo)

less than a year

Tenure

US$3,146,518

Compensation

Mr. George Magrath, MD, MBA, Ms. serves as CEO & Director of Ocuphire Pharma, Inc. since November 1, 2023. He was an Analyst at Edison Investment Research Limited since 2015. He covered the healthcare sect...


Leadership Team

NamePositionTenureCompensationOwnership
George Magrath
CEO & Directorless than a yearUS$3.15m0.12%
$ 50.4k
Bernhard Hoffmann
Senior Vice President of Corporate Development & Secretaryno dataUS$789.92k0.42%
$ 181.0k
Jay Pepose
Chief Medical Advisor & Directorno dataUS$662.10k0.24%
$ 103.0k
Amy Zaremba Rabourn
Senior Vice President of Financeno dataUS$789.92k0.030%
$ 12.9k
Nirav Suresh Jhaveri
Chief Financial Officerless than a yearno data0.58%
$ 252.0k
Joseph Schachle
Chief Operating Officerless than a yearno data0.0077%
$ 3.4k
Ashwath Jayagopal
Chief Scientific & Development Officerless than a yearno data0.30%
$ 131.9k
Bindu Manne
Head of Market Development & Commercialization2.4yrsno datano data
Erik Sims
Director & Corporate Controllerno datano datano data

0.6yrs

Average Tenure

46yo

Average Age

Experienced Management: OCUP's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
George Magrath
CEO & Directorless than a yearUS$3.15m0.12%
$ 50.4k
Jay Pepose
Chief Medical Advisor & Director3yrsUS$662.10k0.24%
$ 103.0k
James S. Manuso
Independent Director3.6yrsUS$154.81k0.31%
$ 134.3k
David Boyer
Member of Medical Advisory Boardno datano datano data
Richard Rodgers
Independent Director3.6yrsUS$1.35m0.44%
$ 189.9k
Jeffrey Heier
Member of Medical Advisory Boardno datano datano data
Peter Kaiser
Member of Medical Advisory Board4.4yrsno datano data
Susan Benton
Independent Director3.6yrsUS$135.34k0.34%
$ 147.7k
Cameron Gallagher
Independent Chairman3.6yrsUS$174.62k0.096%
$ 41.9k
Sean Ainsworth
Lead Independent Director3.6yrsUS$149.56k0.14%
$ 60.9k
David Lally
Member of Medical Advisory Board2.5yrsno datano data
David Brown
Member of Medical Advisory Board2.5yrsno datano data

3.6yrs

Average Tenure

58yo

Average Age

Experienced Board: OCUP's board of directors are considered experienced (3.6 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.